The first gene therapy experiment has just been launched in parallel in France and the United States for patients with advanced cancer. Olivier Rixe, head of clinic at Pitié Salpêtrière, explains what this therapy consists of, namely the introduction of a suicide gene into cancer cells and which causes the programmed death of these cells. He stresses that this new therapy will still require many hours of work. Testimony of a patient who will benefit from this treatment and who confesses not to be at all terrified.
Accessible rights for all uses, in the whole world, in accordance with our T&Cs.
Digital Publication : use for editorial publications - to inform the general public or illustrate the news - for digital broadcast on services, valid for 5 years.
Corporate/Brand content : use for the presentation and promotion of an image, brand, history and values of the Contracting Partner company - or, where applicable, the Beneficiary - for digital broadcast on its services and/or for Events, valid for 1 year.
Cultural Licence : use for cultural purposes and restricted to members of the cultural network. Digital publication for a term of 5 (years) and Events for a term of 1 (one) year from the order payment date.